---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-005302"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2025-02-07T23:59:59+00:00"
generated_at: "2026-05-27T00:55:24.749207+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma appoints Evelyn D'An as independent director and Audit Committee Chair

## Summary
- Evelyn D'An appointed to board effective February 5, 2025 as independent director and Audit Committee Chair.
- Ms. D'An is a former Ernst & Young partner with 18 years of experience, currently President of D'An Financial Services.
- She also serves on boards of Zoomcar (ZCAR), Backblaze (BLZE), and GHD Group (private).
- No related party transactions; compensated under standard non-employee director plan.

## SEC filing metadata
- accession: 0001493152-25-005302
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2025-02-07T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315225005302/0001493152-25-005302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315225005302/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-005302
- JSON: https://secwatch.observer/filing/0001493152-25-005302.json
- Plain text: https://secwatch.observer/filing/0001493152-25-005302.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.